Sector Expert: Michael G. King, Jr.

JMP Securities

Image: Michael G. King, Jr.

Michael G. King Jr. is a managing director and senior biotechnology analyst at JMP Securities. King comes to JMP from Rodman & Renshaw LLC, where he was managing director and senior biotechnology analyst. He has more than 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellside research survey, in addition to being named that publication's "Home Run Hitter" in 2000. King also served as senior vice president of corporate development and communication at ZIOPHARM Oncology (ZIOP:NASDAQ). Prior to joining ZIOPHARM, King was a managing director and senior biotechnology analyst at Wedbush Securities. He holds a bachelor's degree in finance from Baruch College.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • ADMA Biologics Inc.
  • Agenus Inc.
  • Akebia Therapeutics Inc.
  • Applied Genetic Technologies Corp.
  • Ardelyx, Inc.
  • Array BioPharma Inc.
  • BioLineRx Ltd.
  • Calithera Biosciences Inc.
  • Compugen Ltd.
  • Evoke Pharma Inc.
  • Fate Therapeutics Inc.
  • FlexPharma Inc.
  • Galena Biopharma Inc.
  • Ignyta Inc.
  • Infinity Pharmaceuticals Inc.
  • OncoMed Pharmaceuticals Inc.
  • Oramed Pharmaceuticals Inc.
  • Pain Therapeutics Inc.
  • Peregrine Pharmaceuticals Inc.
  • Pieris Pharmaceuticals Inc.
  • Synergy Pharmaceuticals Inc.
  • VBL Therapeutics
  • Verastem Inc.
  • WAVE Life Sciences Ltd.


Recent Interviews

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist (12/15/15)
2016_watchlist_newsletter_graphic_large.2

In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.

JMP Security's Michael King Jr.: Use Stock Volatility to Invest in Innovative Oncology Companies (10/14/15)
dnabulb580

Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially. In this interview with The Life Sciences Report, Michael King Jr. of JMP Securities predicts an ongoing bull market for oncology and highlights some good buys in companies with experienced management and innovative science.

Exuberant, Yes: Michael King on How the Oncology Drug Development Machine Builds Biotech Wealth (3/13/14)

Veteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He understands the sector, the entrepreneurs and the valuations as well as anyone on Wall Street. In this interview with The Life Sciences Report, King zeros in on the oncology space, his focus for nearly two decades. Never single-minded, King's stable of thoroughbred names includes a bonus pick he likes very much in the field of fertility.

Recent Quotes

"ASTX's shares still sell well below where we believe they could trade."

— Michael G. King, Jr., JMP Securities (9/16/13)
more >

"We are reiterating our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (8/19/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We continue to view ASTX as a highly attractive mid-cap play in the biotech space."

— Michael G. King, Jr., JMP Securities (8/1/13)
more >

"We maintain our Outperform rating for ASTX."

— Michael G. King, Jr., JMP Securities (7/8/13)
more >

"We are initiating coverage on CYCC with a Market Outperform rating."

— Michael G. King, Jr., JMP Securities (7/2/13)
more >

"We reiterate our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (4/30/13)
more >



Due to permission requirements, not all quotes are shown.